Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современные возможности лечения распространенного гормонозависимого рака молочной железы у пациенток в постменопаузе
Современные возможности лечения распространенного гормонозависимого рака молочной железы у пациенток в постменопаузе
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Рак молочной железы (РМЖ) – наиболее распространенное онкологическое заболевание у женщин в мире. Гормонозависимый HER2-негативный РМЖ встречается в 70% всех случаев РМЖ. Ключевую роль в лечении данного типа РМЖ играет эндокринная терапия, эффективная и при прогрессировании заболевания. В данном обзоре приводятся и обсуждаются современные возможности лечения гормонозависимого HER2-распространенного РМЖ, в том числе комбинации эндокринной и таргетной терапии с включением ингибитора mTOR эверолимуса.
Ключевые слова: гормонозависимый распространенный рак молочной железы, ингибитор mTOR, эверолимус.
Key words: hormone receptor-positive advanced breast cancer, mTOR inhibitor, everolimus.
Ключевые слова: гормонозависимый распространенный рак молочной железы, ингибитор mTOR, эверолимус.
________________________________________________
Key words: hormone receptor-positive advanced breast cancer, mTOR inhibitor, everolimus.
Полный текст
Список литературы
1. GLOBOCAN 2012. Cancer Incidence, mortality and prevalence worldwide 2012 estimates; http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
2. Cardoso F, Harbeck N, Fallowfield L et al. Locally recurrent or metastatic breast cancer. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 7): vii11–9.
3. AGO Breast Committee. Diagnosis and treatment of patients with primary and metastatic breast cancer. Recommendations 2013; http://www.ago-online.de
4. Cardoso F, Costa A, Norton L et al. First International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21 (3): 242–52.
5. NCCN Clinical Practice Guidelines. Breast Cancer 2012; 3.
6. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst 2011; 103 (3): 178–231.
7. Kennecke HF, Ellard S, O’Reilly S, Gelmon KA. New guidelines for treatment of early hormone-positive breast cancer with tamoxifen and aromatase inhibitors. BC Med J 2006; 48: 121–6.
8. NCCN Clinical Practice Guidelines. Breast Cancer 2012; 3.
9. Cardoso F, Fallowfield L, Costa A et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22 (Suppl. 6): vi25–30.
10. Thong MSY, Mols F, Coeberghet JWW et al. The impact of disease progression on perceived health status and quality of life of long-term cancer survivors. J Cancer Surv 2009; 3 (3): 164–73.
11. Johnston SR, Saccani-Jotti G, Smith IE et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55 (15): 3331–8.
12. Robertson JF, Willsher PC, Cheung KL, Blamey RW. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 1997; 33 (11): 1774–9.
13. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23 (11): 2469–76.
14. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104–7.
15. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 162–5.
16. Cohen MH, Hirschfeld S, Honiget SF et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001; 6: 4–11; http://www.advancedbreastcancercommunity.org/treatment/drugs.htm
17. http://www.advancedbreastcancercommunity.org/treatment/drugs.htm
18. Faslodex. Wilmington, DE. AstraZeneca Pharmaceuticals LP 2011.
19. Fedele P, Calvani N, Marino A et al. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit Rev Oncol Hematol 2012; 84 (2): 243–51.
20. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 2011; 62: 233–47.
21. Yamnik RL, Digilova A, Davis DC et al. S6 kinase 1 regulates estrogen receptor-а in control of breast cancer cell proliferation. J Biol Chem 2009; 284: 6361–9.
22. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231–41.
23. Tanaka C, O’Reilly T, Kovarik JM et al. Identifying optimal biologic doses of Everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008; 26: 1596–602.
24. O’Reilly T, Vaxelaire J, Muller M et al. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002; 43: 71. Abstr. 359.
25. Stoica GE, Franke TF, Wellstein A et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003; 17: 818–30.
26. Ellard S, Gelmon KA, Chia S et al. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. J Clin Oncol 2007; 25: 141s (Suppl.). Abstr. 3513.
27. Crowder RJ et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69 (9): 3955–62.
28. Yue W, Fan P, Wang J et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007; 106: 102–10.
29. Santen RJ, Song RX, Zhang Z et al. Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005; 95: 155–65.
30. Bachelot T, Bourgier C, Cropet et al. TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI). Cancer Res 2010; 70 (Suppl. 24). Abstr. S1-6; http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/24.../S1-6
31. Bachelot T, Bourgier C, Cropet C et al. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. JCO 2012; 2718–24.
32. Piccart M, Baselga J, Noguchi S et al. Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. Presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium 2012. San Antonio, TX. Poster P6-04-02.
33. Baselga J, Campone M, Piccartet M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366 (6): 520–9.
34. Yardley DA, Noguchi S, Pritchard KI et al. Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther 2013; 30 (10): 870–84.
35. Gnant M, Baselga J, Rugo HS et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst 2013; 105 (9): 654–63; http://10.1093/jnci/djt026
36. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008; 26 (24): 4027–34.
37. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13 (2 Pt. 1): 559–65.
38. Glantschnig H, Fisher JE, Wesolowski G et al. M-CSF, TNF-a and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10 (10): 1165–77.
39. Piccart M, Hortobagy, GN, Campone M et al. Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER-) advanced breast cancer (BC): overall survival results from BOLERO-2. Presented at the 9th European Breast Cancer Conference (EBCC-9), 19–21 March 2014. Glasgow, Scotland. Abstr. 1LBA.
40. Burris H, Lebrun F, Rugo HS et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013; 119 (10): 1908–15.
41. Campone M, Beck JT, Gnant M et al. Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2-advanced breast cancer treated with everolimus plus exemestane vs. exemestane monotherapy. Curr Med Res Opin 2013; 29 (11): 1463–73.
42. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2014; 3.
43. Pritchard KI, Gelmon KA, Rayson D et al. Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol 2013; 20 (1): 48–61.
2. Cardoso F, Harbeck N, Fallowfield L et al. Locally recurrent or metastatic breast cancer. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 7): vii11–9.
3. AGO Breast Committee. Diagnosis and treatment of patients with primary and metastatic breast cancer. Recommendations 2013; http://www.ago-online.de
4. Cardoso F, Costa A, Norton L et al. First International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21 (3): 242–52.
5. NCCN Clinical Practice Guidelines. Breast Cancer 2012; 3.
6. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst 2011; 103 (3): 178–231.
7. Kennecke HF, Ellard S, O’Reilly S, Gelmon KA. New guidelines for treatment of early hormone-positive breast cancer with tamoxifen and aromatase inhibitors. BC Med J 2006; 48: 121–6.
8. NCCN Clinical Practice Guidelines. Breast Cancer 2012; 3.
9. Cardoso F, Fallowfield L, Costa A et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22 (Suppl. 6): vi25–30.
10. Thong MSY, Mols F, Coeberghet JWW et al. The impact of disease progression on perceived health status and quality of life of long-term cancer survivors. J Cancer Surv 2009; 3 (3): 164–73.
11. Johnston SR, Saccani-Jotti G, Smith IE et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55 (15): 3331–8.
12. Robertson JF, Willsher PC, Cheung KL, Blamey RW. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 1997; 33 (11): 1774–9.
13. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23 (11): 2469–76.
14. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104–7.
15. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 162–5.
16. Cohen MH, Hirschfeld S, Honiget SF et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001; 6: 4–11; http://www.advancedbreastcancercommunity.org/treatment/drugs.htm
17. http://www.advancedbreastcancercommunity.org/treatment/drugs.htm
18. Faslodex. Wilmington, DE. AstraZeneca Pharmaceuticals LP 2011.
19. Fedele P, Calvani N, Marino A et al. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit Rev Oncol Hematol 2012; 84 (2): 243–51.
20. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 2011; 62: 233–47.
21. Yamnik RL, Digilova A, Davis DC et al. S6 kinase 1 regulates estrogen receptor-а in control of breast cancer cell proliferation. J Biol Chem 2009; 284: 6361–9.
22. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231–41.
23. Tanaka C, O’Reilly T, Kovarik JM et al. Identifying optimal biologic doses of Everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008; 26: 1596–602.
24. O’Reilly T, Vaxelaire J, Muller M et al. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002; 43: 71. Abstr. 359.
25. Stoica GE, Franke TF, Wellstein A et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 2003; 17: 818–30.
26. Ellard S, Gelmon KA, Chia S et al. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. J Clin Oncol 2007; 25: 141s (Suppl.). Abstr. 3513.
27. Crowder RJ et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69 (9): 3955–62.
28. Yue W, Fan P, Wang J et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007; 106: 102–10.
29. Santen RJ, Song RX, Zhang Z et al. Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005; 95: 155–65.
30. Bachelot T, Bourgier C, Cropet et al. TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI). Cancer Res 2010; 70 (Suppl. 24). Abstr. S1-6; http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/24.../S1-6
31. Bachelot T, Bourgier C, Cropet C et al. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. JCO 2012; 2718–24.
32. Piccart M, Baselga J, Noguchi S et al. Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. Presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium 2012. San Antonio, TX. Poster P6-04-02.
33. Baselga J, Campone M, Piccartet M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366 (6): 520–9.
34. Yardley DA, Noguchi S, Pritchard KI et al. Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther 2013; 30 (10): 870–84.
35. Gnant M, Baselga J, Rugo HS et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst 2013; 105 (9): 654–63; http://10.1093/jnci/djt026
36. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008; 26 (24): 4027–34.
37. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13 (2 Pt. 1): 559–65.
38. Glantschnig H, Fisher JE, Wesolowski G et al. M-CSF, TNF-a and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003; 10 (10): 1165–77.
39. Piccart M, Hortobagy, GN, Campone M et al. Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER-) advanced breast cancer (BC): overall survival results from BOLERO-2. Presented at the 9th European Breast Cancer Conference (EBCC-9), 19–21 March 2014. Glasgow, Scotland. Abstr. 1LBA.
40. Burris H, Lebrun F, Rugo HS et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013; 119 (10): 1908–15.
41. Campone M, Beck JT, Gnant M et al. Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2-advanced breast cancer treated with everolimus plus exemestane vs. exemestane monotherapy. Curr Med Res Opin 2013; 29 (11): 1463–73.
42. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2014; 3.
43. Pritchard KI, Gelmon KA, Rayson D et al. Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol 2013; 20 (1): 48–61.
Авторы
Кристиан Якиш, Антонио Ломбарт Куссак
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.